Genprex receives Safety Review Committee approval to advance Acclaim-3 trial

Genprex (GNPX) announced that it has completed the Phase 1 dose escalation portion of the Acclaim-3 clinical trial of Reqorsa Gene Therapy in combination with Tecentriq as maintenance therapy to treat patients with extensive stage small cell lung cancer, ES-SCLC. In addition, the Safety Review Committee, SRC, has approved the opening of the Phase 2 expansion portion of the trial.